Investors largely expected the FOMC to cut rates by a quarter point.The Fedread more
The lack of clarity surrounding the U.S.-China trade war is what's really hitting global growth, says ex- Deputy Treasury Secretary Sarah Bloom Raskin.World Economyread more
China's economy has long relied on factors such high levels of investments and an expanding labor force for growth. Those growth drivers are running out of steam.China Economyread more
India could benefit from the fallout in the U.S.-China trade war, experts told CNBC — but much-needed reforms on land and labor could prove to be a challenge for companies...Asia Economyread more
New crash tests show the Tesla Model 3 and the Audi e-tron, are among the safest models out on the road. The results bolster the theory electric vehicles may be better...Autosread more
U.S. consumers and growth in sectors such as technology have offset declines in other American industries, says Tom Finke, chairman and CEO of investment management firm...US Economyread more
The FAA administrator's comments come on the eve of his visit to Boeing facilities outside Seattle. While there, he's scheduled to meet with Boeing executives and be briefed...Airlinesread more
Last weekend's attacks on oil facilities — and the spike in crude prices that followed — should show that the world needs to stop relying on oil, says Helen Clark.Energyread more
The photo depicts Canadian leader Justin Trudeau wearing a turban and robe, with dark makeup on his hands, face and neck. Liberal Party spokesman confirms the photo is of...Electionsread more
As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
CBS, CNN and other major media companies are starting to pull e-cigarette advertising off their airways, as the death toll from a mysterious vaping-related illness continues...Health and Scienceread more
U.S.-listed shares of GW Pharmaceuticals surged more than 23 percent on Wednesday following a report the British company is working with an investment bank following other drug makers expressing interest in an acquisition.
GW hired Morgan Stanley to help handle the overtures, people familiar with the matter told Reuters. The pharmaceutical company, however, is currently not interested in a sale and there is no guarantee a deal will happen, sources said.
Sources said the identity of potential buyers could not be established. The sources asked not to be identified because the deliberations are confidential, Reuters said.
GW spokesman Stephen Schultz told CNBC the company does not comment on rumors or speculation. A spokesperson for Morgan Stanley did not immediately respond for CNBC's request for comment.
GW may be more appealing to larger drug companies due to its key cannabis-based Epilepsy drug, Epidiolex.
GW's U.S.-listed shares have gained more than 49 percent year-to-date including Wednesday's sharp upward move.
— Reuters contributed to this report.